HRP20070267T3 - Azabiciklički heterocikli kao modulatori kanabinoid receptora - Google Patents

Azabiciklički heterocikli kao modulatori kanabinoid receptora

Info

Publication number
HRP20070267T3
HRP20070267T3 HR20070267T HRP20070267T HRP20070267T3 HR P20070267 T3 HRP20070267 T3 HR P20070267T3 HR 20070267 T HR20070267 T HR 20070267T HR P20070267 T HRP20070267 T HR P20070267T HR P20070267 T3 HRP20070267 T3 HR P20070267T3
Authority
HR
Croatia
Prior art keywords
group
double bond
nr8s
heterocyclyl
cycloalkyl
Prior art date
Application number
HR20070267T
Other languages
English (en)
Inventor
Gu Guixue
R. Ewing William
B. Mikkilineni Amarendra
Pendri Annapurna
A. Ellsworth Bruce
M. Sher Philip
Gerritz Samuel
Sun Chongqing
Murugesan Natesan
Wu Ximao
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20070267T3 publication Critical patent/HRP20070267T3/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Spoj formule Iuključujući farmaceutski prihvatljive soli i stereoizomere, naznačen time, da je: R1 je izabran iz skupine koja se sastoji od halogen, cijano, alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heterociklil, heterociklilalkil, aril,arilalkil, heteroaril, heteroarilalkil, ariloksi,heteroariloksi, -NR8R9, -CO2R8, CONR8R9, -OR8, -NR8COR9, -NR8CONR8R9, -NR8CO2R9, -OCONR8R9, -NR8S(O)PR9, -NR8S(O)pR8R9, -NR8S(O)pOR9 i -OS(O)pNR8R9; R2 je izabran iz skupine koja se sastoji od halogen, cijano, alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heterociklil, heterociklilalkil, aril, arilalkil, heteroaril, heteroarilalkil, ariloksi, heteroariloksi, -NR8R9, -CO2R8, -CONR8R9, -OR8, -NR8COR9, -NR8CONR8R9, -NR8CO2R9, -OCONR8R9, -NR8S(O)PR9, -NR8S(O)PR8R9, -NR8S(O)pOR9 i -OS(O)pNR8R9;R3 je izabran iz skupine koja se sastoji od H, alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heterociklil, heterociklilalkil, aril, arilalkil, heteroaril i heteroarilalkila; R4 je odsutan kada je n dvostruka veza; R4 je izabran iz skupine koja se sastoji od H, alkil, alkenil, alkinil, cikloalkil, cikloalkilalkil, heterociklil, heterociklilalkil, aril, arilalkil, heteroaril i heteroarilalkila kada je n jednostruka veza; R5 je izabran izskupine koja se sastoji od halogen, -OR8, NR8R9, -OCONR8R9, -NCR8, -NCO2R8 i -NR8S(O)PR9 kada je m jednostruka veza, gdje R5 skupina ima molekularnu masu manju od 200 atomskih jedinica mase; R5 je 0 kada je m dvostruka veza; R8 i R9 su neovisno izabrani od H, alkil, arilalkil, cikloalkil, heterociklil, heterocikloalkil, aril, heteroaril i heteroarilalkila, R8 i R9 mogu zajedno tvoriti heterociklički prsten od 4, 5, 6 ili 7 članova ili heteroarilni prsten od 5 ili 6 članova; m je jednostruka ilidvostruka veza; n je jednostruka ili dvostruka veza; kada je m jednostruka veza, nje dvostruka veza; kada je m dvostruka veza, n je jednostruka veza;ip je cijeli broj koji je 1 ili 2. Patent sadrži još 73 patentna zahtjeva.
HR20070267T 2003-12-19 2007-06-08 Azabiciklički heterocikli kao modulatori kanabinoid receptora HRP20070267T3 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53145103P 2003-12-19 2003-12-19
US11/016,198 US7816357B2 (en) 2003-12-19 2004-12-17 Azabicyclic heterocycles as cannabinoid receptor modulators
PCT/US2004/042878 WO2005063762A1 (en) 2003-12-19 2004-12-17 Azabicyclic heterocycles as cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
HRP20070267T3 true HRP20070267T3 (hr) 2007-08-31

Family

ID=34742367

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070267T HRP20070267T3 (hr) 2003-12-19 2007-06-08 Azabiciklički heterocikli kao modulatori kanabinoid receptora

Country Status (21)

Country Link
US (1) US7816357B2 (hr)
EP (1) EP1697371B1 (hr)
JP (1) JP2007514770A (hr)
KR (1) KR20060103265A (hr)
AT (1) ATE360631T1 (hr)
AU (1) AU2004309368A1 (hr)
BR (1) BRPI0417820A (hr)
CA (1) CA2550375A1 (hr)
CY (1) CY1106679T1 (hr)
DE (1) DE602004006166T2 (hr)
DK (1) DK1697371T3 (hr)
ES (1) ES2284081T3 (hr)
HK (1) HK1095138A1 (hr)
HR (1) HRP20070267T3 (hr)
IL (1) IL176110A0 (hr)
IS (1) IS8503A (hr)
NO (1) NO20062691L (hr)
PL (1) PL1697371T3 (hr)
PT (1) PT1697371E (hr)
RU (1) RU2006126123A (hr)
WO (1) WO2005063762A1 (hr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697371B1 (en) 2003-12-19 2007-04-25 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
ATE427759T1 (de) * 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
EP1958948B1 (en) 2005-12-07 2011-10-05 Sumitomo Chemical Company, Limited Pyridazine compound and use thereof
EP1958946B1 (en) 2005-12-07 2011-02-23 Sumitomo Chemical Company, Limited Pyridazine compound and use thereof
EP1988883A1 (fr) * 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
WO2007102999A2 (en) * 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. Cb1 antagonists and inverse agonists
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008066845A2 (en) * 2006-11-28 2008-06-05 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with norfluoxetine
EP2094705B1 (en) 2006-12-14 2012-04-18 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
FR2910001B1 (fr) 2006-12-18 2009-03-20 Sod Conseils Rech Applic Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament
AR064962A1 (es) * 2007-01-22 2009-05-06 Syngenta Participations Ag Derivados de piridazina utiles como fungicidas
JP2008222603A (ja) * 2007-03-09 2008-09-25 Institute Of Physical & Chemical Research 神経変性疾患の予防・治療剤
EP3053440B1 (en) * 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
DE102008000872A1 (de) 2007-04-11 2008-11-13 Basf Se Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
BRPI0812504B8 (pt) * 2007-06-21 2021-05-25 Cara Therapeutics Inc composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
WO2009017755A2 (en) * 2007-07-30 2009-02-05 Ampla Pharmaceuticals Inc. Cb1 antagonists and inverse agonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20100323955A1 (en) * 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2010079241A1 (es) * 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US9265774B2 (en) 2011-04-15 2016-02-23 New York University Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
KR102153557B1 (ko) 2013-03-27 2020-09-09 에프. 호프만-라 로슈 아게 치료에 대한 반응성을 예측하기 위한 유전 마커
NZ722487A (en) * 2014-01-29 2022-04-29 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
EP3174995B1 (en) 2014-07-30 2020-08-19 F.Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994898A (en) * 1975-10-16 1976-11-30 E. R. Squibb & Sons, Inc. 1,2,4-Triazolo (4,3-b) pyridazin-3-ones
IT1164198B (it) 1983-04-28 1987-04-08 Isf Spa Preparazione di un derivato piridazinico farmacologicamente attivo
JPS61106576A (ja) 1984-10-31 1986-05-24 Nippon Soda Co Ltd トリアゾロピリダジン−３−オン誘導体及び製造方法
EA002436B1 (ru) 1996-07-25 2002-04-25 Мерк Шарп Энд Домэ Лимитед Замещенные производные триазоло-пиридазина в качестве лигандов рецепторов гамк
AU6003099A (en) 1998-10-06 2000-04-26 Takeda Chemical Industries Ltd. Fused pyridazine compounds, process for the preparation of the same and uses thereof
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
AU2002319627A1 (en) 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2005519927A (ja) * 2002-02-07 2005-07-07 ファイザー・インク 多嚢胞性卵巣症候群の処置における、シルデナフィル如きｐｄｅ５インヒビターの使用
WO2003082817A2 (en) * 2002-03-25 2003-10-09 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2508731A1 (en) 2003-02-19 2004-09-02 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
EP1697371B1 (en) 2003-12-19 2007-04-25 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200530246A (en) 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators

Also Published As

Publication number Publication date
HK1095138A1 (en) 2007-04-27
PL1697371T3 (pl) 2007-09-28
IL176110A0 (en) 2006-10-05
PT1697371E (pt) 2007-08-03
CY1106679T1 (el) 2012-05-23
DE602004006166D1 (de) 2007-06-06
US7816357B2 (en) 2010-10-19
DE602004006166T2 (de) 2008-01-10
JP2007514770A (ja) 2007-06-07
ATE360631T1 (de) 2007-05-15
NO20062691L (no) 2006-09-14
EP1697371B1 (en) 2007-04-25
RU2006126123A (ru) 2008-01-27
WO2005063762A1 (en) 2005-07-14
AU2004309368A1 (en) 2005-07-14
ES2284081T3 (es) 2007-11-01
EP1697371A1 (en) 2006-09-06
IS8503A (is) 2006-06-08
US20050171110A1 (en) 2005-08-04
BRPI0417820A (pt) 2007-03-27
CA2550375A1 (en) 2005-07-14
KR20060103265A (ko) 2006-09-28
DK1697371T3 (da) 2007-09-17

Similar Documents

Publication Publication Date Title
HRP20070267T3 (hr) Azabiciklički heterocikli kao modulatori kanabinoid receptora
HRP20070241T3 (hr) Azabiciklički heterocikli kao modulatori kanabinoid receptora
AR047063A1 (es) Heterociclos azabiciclicos como moduladores de receptor canabinoide
EP1361220A4 (en) CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
RS52953B (en) PYRIDOPINIDINONSKI INHIBITORI PI3 KALFA
NO20004778L (no) Amidderivater og nociceptin antagonister
WO2003037862A1 (fr) Derives amide, et medicaments correspondants
CA2401711A1 (en) Cyclic amide derivatives
EP1156045A4 (en) AMID DERIVATIVES AND DRUG COMPOSITIONS
ATE503746T1 (de) Neue imidazolidinderivate
UA72917C2 (en) Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
IL192605A0 (en) 1,2-dihydropyridin-2-one derivatives and pharmaceutical compositions containing the same
HRP20010573B1 (hr) Triciklički inhibitori poli(adp-riboza) polimeraza
AR014448A1 (es) Compuesto de alanina, una composicion farmaceutica, uso del compuesto y proceso para la preparacion del compuesto
WO2000066564A8 (en) Benzimidazolones and analogues and their use as progesterone receptor ligands
HUP0002461A2 (hu) Triciklusos benzotiepin- vagy benzoxepinszármazékok és ezeket tartalmazó gyógyszerkészítmények
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
WO2002026706A3 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
YU68102A (sh) Derivati karboksilne kiseline kao ip antagonisti
AR048567A1 (es) Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas.
AR035235A1 (es) Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento
HRP20041030B1 (hr) Derivati benzoksazina kao regulatori 5-ht6 i njihova upotreba
ATE271868T1 (de) Neue cathechole als antimikrobielle mittel
DE60024471D1 (de) Benzopyran derivate
AU2888892A (en) 3-ureido-benzodiazepinones useful as antagonists of cck or of gastrine